Home LiteratureArticle Details
PMID: 8523583 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.

Journal of virology ·Vol. 70 ·No. 1 ·1996-01-00 ·Pages 623-7

Nonkwelo C, Skinner J, Bell A, Rickinson A, Sample J

Abstract

In Epstein-Barr virus (EBV)-transformed B lymphoblastoid and many Burkitt lymphoma cell lines, the EBV EBNA-1 protein is one of six viral nuclear antigens expressed from a common transcription unit under the control of one of two promoters, Wp or Cp. In contrast, EBNA-1 is the only EBV nuclear antigen expressed in Burkitt and other EBV-positive tumors. We previously identified a promoter of EBNA-1 transcription, designated Fp, in early-passage Mutu Burkitt tumor cells, and this promoter is also active in long-term Mutu and Akata Burkitt cell lines which maintain the exclusive expression of EBNA-1 characteristic of the tumor. However, transcription initiation within Fp reporter gene plasmids in EBV-negative cells occurs at positions 100 to 200 bases downstream of the Fp start site in the BamHI-Q restriction fragment. Here we demonstrate that transcription initiation within newly established Burkitt lymphoma cell lines is consistent with the transcription initiation we observed in reporter plasmids. Furthermore, previous observations of transcription from Fp to generate EBNA-1 transcripts can be attributed to lytic-cycle gene expression. These data, in conjunction with our previous characterization of promoter regulatory elements, define a fourth EBNA-1 promoter, Qp, that is active in latently infected Burkitt tumor cells.

MeSH Terms
Antigens, Viral/genetics,metabolism Binding Sites DNA-Binding Proteins/genetics,metabolism Epstein-Barr Virus Nuclear Antigens Gene Expression Herpesvirus 4, Human/genetics Promoter Regions, Genetic RNA, Messenger/metabolism RNA, Viral/metabolism Transcription, Genetic Tumor Cells, Cultured Virus Latency
Chemicals
Antigens, Viral DNA-Binding Proteins Epstein-Barr Virus Nuclear Antigens RNA, Messenger RNA, Viral
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Nonkwelo C
Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Skinner J
Bell A
Rickinson A
Sample J
References (29)
29 references, click to expand
  1. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance.
    Nature. 1985 Oct 17-23;317(6038):629-31 PMID: 2997615
  2. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.
    Int J Cancer. 1988 Sep 15;42(3):329-38 PMID: 2843473
  3. Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site.
    Proc Natl Acad Sci U S A. 1986 Jul;83(14):5096-100 PMID: 3460083
  4. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells.
    EMBO J. 1986 Oct;5(10):2599-607 PMID: 3023050
  5. A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus.
    J Virol. 1987 Nov;61(11):3424-30 PMID: 2822952
  6. Epstein-Barr virus gene expression in nasopharyngeal carcinoma.
    J Gen Virol. 1988 May;69 ( Pt 5):1051-65 PMID: 2836550
  7. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters.
    J Virol. 1989 Apr;63(4):1729-36 PMID: 2538653
  8. EBV gene expression in an NPC-related tumour.
    EMBO J. 1989 Sep;8(9):2639-51 PMID: 2479554
  9. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes.
    Proc Natl Acad Sci U S A. 1990 Mar;87(5):1725-9 PMID: 2155423
  10. Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes.
    J Virol. 1990 Apr;64(4):1667-74 PMID: 2157049
  11. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
    J Gen Virol. 1990 Jul;71 ( Pt 7):1481-95 PMID: 2165133
  12. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease.
    Lancet. 1991 Feb 9;337(8737):320-2 PMID: 1671232
  13. Differential expression of Epstein Barr viral transcripts for two proteins (TP1 and LMP) in lymphocyte and epithelial cells.
    Nucleic Acids Res. 1991 May 11;19(9):2435-40 PMID: 1710355
  14. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site.
    Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6343-7 PMID: 1648738
  15. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes.
    Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6550-4 PMID: 1713681
  16. Reciprocal antagonism of steroid hormones and BZLF1 in switch between Epstein-Barr virus latent and productive cycle gene expression.
    J Virol. 1992 Jan;66(1):70-7 PMID: 1309265
  17. Transcription of the Epstein-Barr virus gene EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells.
    J Virol. 1992 Feb;66(2):706-14 PMID: 1370554
  18. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    J Exp Med. 1992 Jul 1;176(1):157-68 PMID: 1319456
  19. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    J Exp Med. 1992 Jul 1;176(1):169-76 PMID: 1377222
  20. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.
    J Virol. 1992 Aug;66(8):4654-61 PMID: 1321268
  21. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
    J Virol. 1992 Dec;66(12):7461-8 PMID: 1331531
  22. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
    J Exp Med. 1993 Feb 1;177(2):339-49 PMID: 8381153
  23. Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas.
    J Virol. 1993 Oct;67(10):6303-8 PMID: 8396685
  24. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
    J Virol. 1994 Nov;68(11):7374-85 PMID: 7933121
  25. Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor.
    Mol Cell Biol. 1994 Nov;14(11):7144-52 PMID: 7935429
  26. Characterization of the Epstein-Barr virus Fp promoter.
    Virology. 1995 Jan 10;206(1):183-95 PMID: 7831773
  27. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1.
    J Virol. 1995 Jun;69(6):3752-8 PMID: 7745723
  28. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines.
    J Virol. 1995 Aug;69(8):5039-47 PMID: 7609074
  29. Mapping of genes in BamHI fragment M of Epstein-Barr virus DNA that may determine the fate of viral infection.
    J Virol. 1986 Jan;57(1):145-54 PMID: 2867227
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1996-01-00
Pages
623-7
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC189856
Subset
IM
Grants
NCI NIH HHS · CA-21765 · United States
NCI NIH HHS · CA-56639 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]